<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d608">
    <sentence id="DDI-DrugBank.d608.s0" text="The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ">
        <entity id="DDI-DrugBank.d608.s0.e0" charOffset="24-31"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d608.s0.e1" charOffset="75-82"
            type="drug" text="tolmetin"/>
        <entity id="DDI-DrugBank.d608.s0.e2" charOffset="89-96"
            type="drug" text="tolmetin"/>
        <pair id="DDI-DrugBank.d608.s0.p0" e1="DDI-DrugBank.d608.s0.e0"
            e2="DDI-DrugBank.d608.s0.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s0.p1" e1="DDI-DrugBank.d608.s0.e0"
            e2="DDI-DrugBank.d608.s0.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s0.p2" e1="DDI-DrugBank.d608.s0.e1"
            e2="DDI-DrugBank.d608.s0.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s1" text="However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ">
        <entity id="DDI-DrugBank.d608.s1.e0" charOffset="95-102"
            type="brand" text="TOLECTIN"/>
        <entity id="DDI-DrugBank.d608.s1.e1" charOffset="108-115"
            type="drug" text="warfarin"/>
        <pair id="DDI-DrugBank.d608.s1.p0" e1="DDI-DrugBank.d608.s1.e0"
            e2="DDI-DrugBank.d608.s1.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s2" text="Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ">
        <entity id="DDI-DrugBank.d608.s2.e0" charOffset="58-65"
            type="brand" text="TOLECTIN"/>
        <entity id="DDI-DrugBank.d608.s2.e1" charOffset="82-95"
            type="group" text="anticoagulants"/>
        <pair id="DDI-DrugBank.d608.s2.p0" e1="DDI-DrugBank.d608.s2.e0"
            e2="DDI-DrugBank.d608.s2.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s3" text="In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ">
        <entity id="DDI-DrugBank.d608.s3.e0" charOffset="55-67"
            type="group" text="sulfonylureas"/>
        <entity id="DDI-DrugBank.d608.s3.e1" charOffset="72-78"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d608.s3.e2" charOffset="133-140"
            type="brand" text="TOLECTIN"/>
        <entity id="DDI-DrugBank.d608.s3.e3" charOffset="149-167"
            type="group" text="hypoglycemic agents"/>
        <pair id="DDI-DrugBank.d608.s3.p0" e1="DDI-DrugBank.d608.s3.e0"
            e2="DDI-DrugBank.d608.s3.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s3.p1" e1="DDI-DrugBank.d608.s3.e0"
            e2="DDI-DrugBank.d608.s3.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s3.p2" e1="DDI-DrugBank.d608.s3.e0"
            e2="DDI-DrugBank.d608.s3.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s3.p3" e1="DDI-DrugBank.d608.s3.e1"
            e2="DDI-DrugBank.d608.s3.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s3.p4" e1="DDI-DrugBank.d608.s3.e1"
            e2="DDI-DrugBank.d608.s3.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s3.p5" e1="DDI-DrugBank.d608.s3.e2"
            e2="DDI-DrugBank.d608.s3.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s4" text="Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ">
        <entity id="DDI-DrugBank.d608.s4.e0" charOffset="26-33"
            type="brand" text="TOLECTIN"/>
        <entity id="DDI-DrugBank.d608.s4.e1" charOffset="70-81"
            type="drug" text="methotrexate"/>
        <pair id="DDI-DrugBank.d608.s4.p0" e1="DDI-DrugBank.d608.s4.e0"
            e2="DDI-DrugBank.d608.s4.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s5" text="TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ">
        <entity id="DDI-DrugBank.d608.s5.e0" charOffset="0-7"
            type="brand" text="TOLECTIN"/>
        <entity id="DDI-DrugBank.d608.s5.e1" charOffset="19-54"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <entity id="DDI-DrugBank.d608.s5.e2" charOffset="110-121"
            type="drug" text="methotrexate"/>
        <entity id="DDI-DrugBank.d608.s5.e3" charOffset="178-189"
            type="drug" text="methotrexate"/>
        <pair id="DDI-DrugBank.d608.s5.p0" e1="DDI-DrugBank.d608.s5.e0"
            e2="DDI-DrugBank.d608.s5.e1" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s5.p1" e1="DDI-DrugBank.d608.s5.e0"
            e2="DDI-DrugBank.d608.s5.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-DrugBank.d608.s5.p2" e1="DDI-DrugBank.d608.s5.e0"
            e2="DDI-DrugBank.d608.s5.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s5.p3" e1="DDI-DrugBank.d608.s5.e1"
            e2="DDI-DrugBank.d608.s5.e2" ddi="true" type="mechanism"/>
        <pair id="DDI-DrugBank.d608.s5.p4" e1="DDI-DrugBank.d608.s5.e1"
            e2="DDI-DrugBank.d608.s5.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d608.s5.p5" e1="DDI-DrugBank.d608.s5.e2"
            e2="DDI-DrugBank.d608.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d608.s6" text="Laboratory Tests Because serious GI tract ulceration and bleeding can occur without warning symptoms, physicians should follow chronically treated patients for the signs and symptoms of ulceration and bleeding and should inform them of the importance of this follow-up."/>
</document>
